- $123.31m
- -$27.94m
- 44
- 39
- 61
- 45
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.79 | ||
| Price to Tang. Book | 0.79 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -34.95% | ||
| Return on Equity | -36.92% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 2 | n/a | n/a | 0.02 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 19th, 2006
- Public Since
- July 14th, 2023
- No. of Shareholders
- 50
- No. of Employees
- 14
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 32,195,345
- Address
- 155 BOVET RD., SUITE 303, SAN MATEO, 94402
- Web
- https://sagimet.com/
- Phone
- +1 6505618600
- Auditors
- Deloitte & Touche LLP
Upcoming Events for SGMT
Q1 2025 Sagimet Biosciences Inc Earnings Release
Sagimet Biosciences Inc Annual Shareholders Meeting
Sagimet Biosciences Inc Annual Shareholders Meeting
Similar to SGMT
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Sagimet Biosciences share price?
As of Today at 23:02 UTC, shares in Sagimet Biosciences are trading at $3.83. This share price information is delayed by 15 minutes.
How has the Sagimet Biosciences share price performed this year?
Shares in Sagimet Biosciences last closed at $3.83 and the price had moved by -13.93% over the past 365 days. In terms of relative price strength the Sagimet Biosciences share price has underperformed the S&P500 Index by -22.39% over the past year.
What are the analyst and broker recommendations for Sagimet Biosciences?
The overall consensus recommendation for Sagimet Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Sagimet Biosciences dividend yield?
Sagimet Biosciences does not currently pay a dividend.
Does Sagimet Biosciences pay a dividend?
Sagimet Biosciences does not currently pay a dividend.
When does Sagimet Biosciences next pay dividends?
Sagimet Biosciences does not currently pay a dividend.
How do I buy Sagimet Biosciences shares?
To buy shares in Sagimet Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sagimet Biosciences?
As of the previous close price of $3.83, shares in Sagimet Biosciences had a market capitalisation of $123.31m.
Where are Sagimet Biosciences shares listed?
Here are the trading details for Sagimet Biosciences:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: SGMT
What kind of share is Sagimet Biosciences?
Based on an overall assessment of its quality, value and momentum Sagimet Biosciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sagimet Biosciences share price forecast for 2025?
The analyst consensus target price for shares in Sagimet Biosciences is $31.14. That is 713.05% above the last closing price of $3.83.
Analysts covering Sagimet Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$3.27 for the next financial year.
Find out moreWhat is the trend in the Sagimet Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sagimet Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -27.81%.
As of the last closing price of $3.83, shares in Sagimet Biosciences were trading -4.12% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sagimet Biosciences PE Ratio?
The Sagimet Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.83.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sagimet Biosciences?
We do not have data on Sagimet Biosciences' directors